

ONCOLOGY

Labcorp Biopharma Services

Expediting your global precision oncology therapeutic and diagnostic development.





OVERVIEW

Your mission is to transform oncology patient care. Our commitment is to help you do it better, faster and more efficiently.

As you develop your oncology therapeutic, you'll face critical decisions that will impact its success. In these moments, you need insights from an experienced partner.

At Labcorp, we strive to be *more* than a partner, doing all we can to advance your program with speed and efficiency.

Every decision we help you make—from initial discovery to clinical trial testing and diagnostic commercialization—is designed to help your development progress seamlessly from one stage to the next.

We believe the more informed your oncology development strategy is, the more profound a difference your therapeutic can make in the lives of those with cancer around the world.

Oncology experience you can count on

Development of precision oncology therapeutics is complex. But with years of global oncology testing experience, Labcorp is uniquely positioned to support the entire development of your therapeutic, leveraging testing solutions anchored by a biomarker-driven strategy. Our experience effectively connects insights from one stage to the next, bringing efficiencies to your development process and empowering you to make more informed decisions.

We have supported development for:



10 of 16

oncology drugs approved by the U.S. FDA in 2022



2,000+

Oncology clinical trials across various tumor types over the last 5 years



6

FDA-approved CAR T-cell therapies



CDx


for PD-L1, HER-2, KRAS, EGFR, BRAF, ALK and more

3

Accelerate your biomarker-driven oncology therapeutic development at every stage

As the only global research and development organization that can support you from preclinical discovery through diagnostic commercialization, we can help you achieve your milestones faster, maximizing efficiency and preserving knowledge as you advance from one step to the next.

Explore our solutions



BIOMARKER DISCOVERY

Identify and develop fit-for-purpose biomarkers using best-in-class platform technologies as early as possible.

CLINICAL TRIAL ASSAYS

Find the right patients for your clinical trial so your trial data will provide the most meaningful outcomes.

CDX/LDT DEVELOPMENT

Be prepared on day one with parallel development of your diagnostic and therapeutic with oordinated resources—across our own IVD teams or a third-party.

COMMERCIALIZATION

Go to market with both your approved therapeutic and its companion or complementary diagnostic.



Page 6: Testing solutions

Advance precision oncology development through innovative technologies designed for tissue, immune, and liquid biopsy profiling and over 500 validated clinical tests.



Page 9: Global laboratory network

Our global network of laboratories spans all disciplines and is committed to driving advancing and sample logistics excellence.



Page 10: Consulting

Experienced, integrated teams provide strategic and scientific support, including biomarker discovery, CDx commercialization, medical affairs and regulatory teams.



Page 12: Data services

Expertise analyzing an unparalleled data set to generate meaningful real-world evidence that improves therapeutic and diagnostic development effectiveness.



Page 13: Commercialization

Our multidisciplinary team focuses on accelerating patient access to your biomarker-directed therapy through healthcare provider education.

TESTING SOLUTIONS

Precision oncology portfolio

From biomarker discovery to clinical trial assay support and companion diagnostic development and commercialization, Labcorp offers NGS assays and customized services to help pharmaceutical and biotech companies accelerate innovation, unlock value and bring the promise of precision medicine to more patients.



Liquid Biopsy Solutions

Plasma Complete



Liquid Biopsy Plasma cfDNAseq SNVs / Indels / CNA **Translocations** 521 genes



with matched normal analysis*





Liquid Biopsy Plasma cfDNAseq SNVs / Indels / CNA Translocations 33 genes









Tumor-informed MRD with WGS + proprietary machine learning



Hematological Profiling


IntelliGEN® Myeloid



DNASeq SNVs, Indels, CNA, Fusions 50 clinically relevant genes

Molecular Profiling





Solid Tissue and Immune Profiling

OmniSeq INSIGHT



Molecular Profiling DNAseq & RNAseq 523 genes

Profiling **RNA Gene** Expression 395 genes



PGDx elio tissue complete



Molecular Profiling DNAseq 505 genes



TCR-β Repertoire



TCR-β-SR Assay (RNA + DNA) FFPE / FF/ PBMC cfDNA / DNA / T-cells CDR3

TCR-β-LR Assay (RNA) FF / PBMC / Blood CDR1, CDR2, CDR3

Whole Transcriptome Sequencing

FFPE / PBMC / Blood RNAseq **Global Transcript Expression** Differential RNA Expression **Neoantigen Prediction**



Whole Exome Sequencing

FFPE / PBMC / Blood **DNAseq NGS** 22,000 genes

*LOH and matched normal analysis available for Research Use Only

More than 500 validated Dx tests—including single-analyte and HLA-typing—deployed for clinical testing

Extensive clinical diagnostic reach significant biomarker tested oncology population

Labcorp Oncology test solutions 500+ validated Dx tests deployed or clinical testing

- NGS CGP
 Solid Tumor
 Genomic & Immune Profiling
- MRD Liquid Biopsy / ctDNA
- HLA Profiling
 Germline Testing
 Tumor-Informed Typing
- Pharmacokinetic
 Pharmacodynamic Testing
- Pharmacogenomics Testing

- NGS CGP Solid Tumor Liquid Biopsy / ctDNA
- NGS CGP
 Myeloid Malignancies
- Hereditary Cancer
 Disease Panels
- Routine Chemistries
- Single Gene Testing NGS, PCR, FISH, IHC

GLOBAL LABORATORY SERVICES NETWORK

Indianapolis, IN

Los Angeles, CA

Madison, WI

Global oncology testing experience you can trust

An unmatched laboratory network with oncology capabilities across the globe.

NORTH AMERICA WESTERN EUROPE ASIA-PACIFIC CHINA **Specialty Labs North America** Asia/Pacific China Europe Baltimore, MD Ann Arbor, MI Eye, U.K. Bangalore, IN Shanghai Greenfield, IN Brentwood, TN Geneva, CH Kawagoe, JP

Harrogate, U.K.

Huntingdon, U.K.

Muenster. DE

Singapore



Buffalo, NY

Burlington, NC

Phoenix. AZ

Research Triangle Park, NC Shelton, CT

Our Global presence means Labcorp has unmatched experience navigating regional regulatory guidelines, engaging unique patient populations and recruiting the **top-performing investigation sites from more than 85 countries.**

CONSULTING SERVICES

Connected insights that work for you

Our integrated team of medical, scientific, regulatory and statistical experts constantly looks for ways to share insights to reduce development time and risk—so your therapy has the best possible chance of changing the lives of patients around the world.



Preclinical development

Rapidly move through preclinical development with comprehensive early development research support.

- DMPK/IVP/discovery
- Bioanalysis
- Preclinical safety
- Chemistry, manufacturing and controls



Biomarker discovery and confirmation

Access scientific leadership and guidance across our extensive global laboratory testing capabilities to extend your translational team and help you define a comprehensive oncology biomarker strategy. Identify and develop fit-for-purpose biomarkers that will inform your clinical development protocol.



Clinical development insights

Inform your oncology development strategy to make a more profound difference in the lives of those with cancer around the world.

- Clinical trial assays for screening, inclusion and stratification
- Endpoint analysis
- Paired tissue and liquid biopsy strategies for improved patient access



Companion diagnostic development and commercialization

Efficiently incorporate a potential companion diagnostic into your commercialization strategy and ensure both diagnostic and therapeutic will be ready on Day 1, maximizing patient access and your ROI.



Regulatory

Access knowledgeable and experienced regulatory leaders who can support your strategy development and discussions with agencies in key global regions.



Medical affairs

Leverage an experienced medical affairs team to receive scientific support, education and a detailed review of Labcorp Oncology's latest advancements.





DATA SERVICES

Proprietary data and experience to reduce risk and increase efficiencies

Using more than 30 billion lab test results across a growing menu of approximately 5,000 assays and a testing database that reaches around 50% of U.S. population, we empower you with the insights and support you need during asset progression to make more informed decisions at critical development milestones:

Labcorp can help you by

Biomarker discovery	Identifying unmet patient needs, disease prevalence, treatment patterns and potential treatment outcomes—informing a sounder design for your overall program. Gathering high-quality data that's relevant to your product's cancer target and eventual indication, providing valuable insights that increase the probability of your trial's success.
Commercial programs	Analyzing cohorts specialized by therapeutic indication or exploratory endpoint analysis (e.g., HCP, ICD-10, diagnosis, biomarker status). Accelerating testing with greater pipeline visibility, outreach targeting and forecasting.
Clinical trial utilization	Using real-time clinical and molecular data to screen and match patients to biomarker targeted clinical trials. Better understanding site performance through investigator site data spanning a majority of global clinical trials.

COMMERCIALIZATION

Commercialization

Backed by the broader Labcorp organization and infrastructure, you'll partner with our dedicated oncology teams focused on every aspect of both therapeutic and diagnostic development—all with one mission: enabling patient access to your critical therapy.

Leverage Labcorp's expansive commercialization expertise and capabilities with our multidisciplinary team offering a comprehensive portfolio and bespoke partnership solutions, including:



Day 1 readiness

Benefit from operational availability of the diagnostic test to support access to your therapeutic upon approval through Labcorp's extensive laboratory network.



Biomarker-enriched data solutions

Accelerate testing with pipeline visibility, outreach targeting and forecasting enabled by Labcorp's unique bioinformatics insights.



Lab alerts

Facilitate awareness and order adaptation of the companion or complementary diagnostic test with retrospective and/or prospective engagements between healthcare providers and Labcorp's medical affairs team.



Sponsored testing programs

Accelerate patient access to your therapy with a customized approach to overcome challenges in diagnostic utilization, healthcare provider education and testing coverage concerns.

12 13

COMMERCIALIZATION

An emphasis on diversity, inclusion and equity of access

People living with cancer can't consider your trial as a treatment option if they don't know how to find it. With a depth of experience in diagnostic testing and drug development, we are uniquely positioned to provide key insights regarding patient population diversity and locations, and match that to site performance.

Through key partnerships and technologies, we can rapidly establish trial sites within specific community settings, bringing the trial to a more diverse patient population, minimizing impact and maximizing participation.



Our collaboration with Circuit Clinical enables trusted private and community practices to bring cancer trial sites into their more diverse communities.



CCORN brings late-stage trial capabilities to community cancer clinics with underserved patient populations.



Leverage Labcorp's 2,000 patient service centers

Reduced travel time—on average, patients visiting one of our patient service centers for clinical trials reduce their travel distance from 25 miles one-way to just 3 miles.





Increasing clinical trial awareness

Labcorp's Global Trial Source platform (GlobalTrialSource.com) helps people with cancer find and connect with clinical trials.

Partner advocacy groups announce enrollment for cancer-specific clinical trials.

Easy-to-read reports that recommend approved treatments based on a patient's biomarker status, helping to increase overall awareness of your clinical trial.

We see it as our responsibility to embrace your mission, understand your business goals and work tirelessly to make your job and your decisions easier and more efficient during every step of your oncology development endeavors.



Let's start a conversation. Contact us.

connect.labcorp.com/oncology

